Actively Recruiting
The Role of Bimatoprost in Graves' Periorbitopathy
Led by Johns Hopkins University · Updated on 2025-07-17
3
Participants Needed
1
Research Sites
104 weeks
Total Duration
On this page
AI-Summary
What this Trial Is About
Researchers are evaluating the use of Bimatoprost, a topical eye drop commonly used for glaucoma, to see if it can reduce periorbital fat and improve the appearance of bulging eyes in patients with Graves' Ophthalmopathy. This early phase 1 trial focuses on patients experiencing eye bulging (proptosis) caused by this condition. The study aims to understand if applying Bimatoprost can help improve this specific eye symptom. Participants will apply one drop of Bimatoprost eye drops nightly to their more proptotic (more bulging) eye, while the other eye will not receive any treatment. This allows comparison between the treated and untreated eye within the same patient. The study does not involve randomization and uses a single-blind design. The treatment period and observation for changes last one year. Throughout the study, researchers will monitor changes in periorbital fat and improvement in eye bulging over a 12-month period. Participants will likely attend regular visits for assessment and monitoring of treatment effects. The main measurement is the reduction in periorbital fat causing improvement in proptosis. Safety and any side effects will also be observed during the study duration, which is planned to continue until July 2031.
CONDITIONS
Brief Title
Bimatoprost as a Treatment for Graves' Orbitopathy
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Diagnosis of Graves' Ophthalmopathy with exophthalmos/proptosis
- Age 18 years or older
- All genders are eligible
You will not qualify if you...
- Active Graves Disease
- Currently pregnant
- Taking steroid medications
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Your Study Journey
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Up to 1 year
Participants use Bimatoprost ophthalmic drops nightly in the more proptotic eye as part of the study treatment.
Regular visits to monitor treatment effects
Trial Site Locations
Total: 1 location
1
University of Washington
Seattle, Washington, United States, 98104
Actively Recruiting
Research Team
E
Emily Li, MD
How is the study designed?
Study Type
INTERVENTIONAL
Masking
SINGLE
Allocation
NON_RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Frequently Asked Questions
Have more questions? Get in touch with our team for quick support
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here